Mesna
Ifex, Ifex/mesnex, Ifosfamide/mesna, Mesnex (mesna) is a small molecule pharmaceutical. Mesna was first approved as Ifex on 1988-12-30. It is used to treat cystitis and hemorrhage in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Ifex, Mesnex (generic drugs available since 2001-04-26)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cystitis | EFO_1000025 | D003556 | N30 |
| hemorrhage | MP_0001914 | D006470 | R58 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05C: Expectorants, excl. combinations with cough suppressants
— R05CB: Mucolytics
— R05CB05: Mesna
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AF: Detoxifying agents for antineoplastic treatment
— V03AF01: Mesna
HCPCS
Code | Description |
|---|---|
| J9209 | Injection, mesna, 200 mg |
Clinical
Clinical Trials
168 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 7 | 18 | 1 | — | 2 | 26 | |
| Leukemia | D007938 | C95 | 4 | 12 | 3 | — | 2 | 20 | |
| Sarcoma | D012509 | 5 | 6 | 2 | — | 3 | 15 | ||
| Neuroblastoma | D009447 | EFO_0000621 | 4 | 5 | 1 | — | — | 10 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 7 | 1 | — | — | 8 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 1 | 2 | 2 | — | — | 4 |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | 2 | 1 | — | — | 3 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | 1 | — | 1 | 3 |
| Medulloblastoma | D008527 | 1 | — | 1 | — | 1 | 3 | ||
| Central nervous system neoplasms | D016543 | 1 | 1 | 1 | — | — | 3 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 9 | 14 | — | — | — | 17 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 2 | 11 | — | — | 2 | 13 | |
| Myeloid leukemia acute | D015470 | C92.0 | 6 | 8 | — | — | — | 11 | |
| Myelodysplastic syndromes | D009190 | D46 | 5 | 6 | — | — | — | 9 | |
| Hodgkin disease | D006689 | C81 | 3 | 4 | — | — | 2 | 7 | |
| Neoplasms | D009369 | C80 | 6 | 1 | — | — | 1 | 7 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | 6 | — | — | — | 6 | |
| Germ cell and embryonal neoplasms | D009373 | 1 | 3 | — | — | 2 | 6 | ||
| Hematologic neoplasms | D019337 | 2 | 5 | — | — | 1 | 6 | ||
| Retinoblastoma | D012175 | 2 | 2 | — | — | 1 | 5 |
Show 38 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteosarcoma | D012516 | 2 | — | — | — | 1 | 3 | ||
| Primary myelofibrosis | D055728 | D47.4 | 2 | — | — | — | — | 2 | |
| Rhabdomyosarcoma | D012208 | 1 | — | — | — | 1 | 2 | ||
| Hepatoblastoma | D018197 | C22.2 | 1 | — | — | — | 1 | 2 | |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | — | — | — | — | 2 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | 1 | — | — | — | — | 1 | ||
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
| Vasculitis | D014657 | EFO_0006803 | M31 | 1 | — | — | — | — | 1 |
| Muscular diseases | D009135 | EFO_0002970 | G72.9 | 1 | — | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
Show 9 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 2 | 2 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 1 | 1 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | — | — | — | 1 | 1 |
| Langerhans-cell histiocytosis | D006646 | C96.6 | — | — | — | — | 1 | 1 | |
| Wiskott-aldrich syndrome | D014923 | D82.0 | — | — | — | — | 1 | 1 | |
| Severe combined immunodeficiency | D016511 | D81.0 | — | — | — | — | 1 | 1 | |
| Hemophagocytic lymphohistiocytosis | D051359 | D76.1 | — | — | — | — | 1 | 1 | |
| Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | — | — | — | — | 1 | 1 |
| Chediak-higashi syndrome | D002609 | Orphanet_167 | D72.0 | — | — | — | — | 1 | 1 |
| Common variable immunodeficiency | D017074 | EFO_0000367 | D83 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MESNA |
| INN | mesna |
| Description | Mesna is an organosulfonic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=S(=O)([O-])CCS.[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 19767-45-4 |
| RxCUI | 44 |
| ChEMBL ID | CHEMBL975 |
| ChEBI ID | — |
| PubChem CID | 23662354 |
| DrugBank | — |
| UNII ID | NR7O1405Q9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,736 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ifex
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more